JP2022549276A5 - - Google Patents
Info
- Publication number
- JP2022549276A5 JP2022549276A5 JP2022518285A JP2022518285A JP2022549276A5 JP 2022549276 A5 JP2022549276 A5 JP 2022549276A5 JP 2022518285 A JP2022518285 A JP 2022518285A JP 2022518285 A JP2022518285 A JP 2022518285A JP 2022549276 A5 JP2022549276 A5 JP 2022549276A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- immunocytokine
- constant domain
- heavy chain
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025118407A JP2025182218A (ja) | 2019-09-19 | 2025-07-14 | Ｉｌ－１５／ｉｌ－１５ｒａに基づくヘテロ二量体タンパク質複合体を含む、イムノサイトカイン |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2019129569 | 2019-09-19 | ||
| RU2019129569A RU2753282C2 (ru) | 2019-09-19 | 2019-09-19 | ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ |
| PCT/RU2020/050233 WO2021054867A1 (ru) | 2019-09-19 | 2020-09-20 | Иммуноцитокин, включающий гетеро димерный белковый комплекс на основе il-15 и il-15rα |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025118407A Division JP2025182218A (ja) | 2019-09-19 | 2025-07-14 | Ｉｌ－１５／ｉｌ－１５ｒａに基づくヘテロ二量体タンパク質複合体を含む、イムノサイトカイン |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022549276A JP2022549276A (ja) | 2022-11-24 |
| JP2022549276A5 true JP2022549276A5 (https=) | 2023-09-28 |
Family
ID=74873995
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022518285A Pending JP2022549276A (ja) | 2019-09-19 | 2020-09-20 | Ｉｌ－１５／ｉｌ－１５ｒａに基づくヘテロ二量体タンパク質複合体を含む、イムノサイトカイン |
| JP2025118407A Pending JP2025182218A (ja) | 2019-09-19 | 2025-07-14 | Ｉｌ－１５／ｉｌ－１５ｒａに基づくヘテロ二量体タンパク質複合体を含む、イムノサイトカイン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025118407A Pending JP2025182218A (ja) | 2019-09-19 | 2025-07-14 | Ｉｌ－１５／ｉｌ－１５ｒａに基づくヘテロ二量体タンパク質複合体を含む、イムノサイトカイン |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20230011234A1 (https=) |
| EP (1) | EP4032539A4 (https=) |
| JP (2) | JP2022549276A (https=) |
| KR (1) | KR20220145323A (https=) |
| CN (1) | CN115297885A (https=) |
| AR (1) | AR120011A1 (https=) |
| AU (1) | AU2020351560A1 (https=) |
| BR (1) | BR112022005173A2 (https=) |
| CA (1) | CA3151780A1 (https=) |
| CO (1) | CO2022003156A2 (https=) |
| JO (1) | JOP20220071A1 (https=) |
| MA (1) | MA56286B1 (https=) |
| MX (1) | MX2022003306A (https=) |
| PE (1) | PE20220603A1 (https=) |
| PH (1) | PH12022550688A1 (https=) |
| PY (1) | PY2056649A (https=) |
| RU (1) | RU2753282C2 (https=) |
| TW (1) | TWI891660B (https=) |
| UY (1) | UY38889A (https=) |
| WO (1) | WO2021054867A1 (https=) |
| ZA (1) | ZA202203254B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220002370A1 (en) | 2018-09-27 | 2022-01-06 | Xilio Development, Inc. | Masked cytokine polypeptides |
| WO2022115865A2 (en) | 2020-11-25 | 2022-06-02 | Xilio Development, Inc. | Tumor-specific cleavable linkers |
| EP4463135A2 (en) | 2022-01-10 | 2024-11-20 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| CN116178572B (zh) * | 2022-02-28 | 2025-12-23 | 厦门柏慈生物科技有限公司 | 构建嵌合蛋白的嵌合区域、构建方法、嵌合蛋白及其应用 |
| CN115141283A (zh) * | 2022-03-10 | 2022-10-04 | 厦门柏慈生物科技有限公司 | 一种融合蛋白、制备方法及其应用 |
| WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| CN116854821A (zh) * | 2022-08-15 | 2023-10-10 | 海徕科(北京)生物技术有限公司 | IL-15突变体-Fc/IL-15Rα亚基-Fc异源二聚体及其用途 |
| WO2025031274A1 (zh) * | 2023-08-04 | 2025-02-13 | 深圳众格生物科技有限公司 | Sushi结构域突变体、融合蛋白、药物组合物和用途 |
| WO2025140627A1 (zh) * | 2023-12-28 | 2025-07-03 | 南通壹宸生物医药科技有限公司 | 融合抗体及其应用 |
| WO2026037415A1 (zh) * | 2024-08-16 | 2026-02-19 | 北京清辉联诺生物科技有限责任公司 | 一种IL15/IL15Rα复合物及其在细胞疗法领域的应用 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| EP0216846B2 (en) | 1985-04-01 | 1995-04-26 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| JP2000516470A (ja) * | 1996-08-16 | 2000-12-12 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 可溶性一価および多価ｍｈｃクラスｉｉ融合タンパク質およびそれらの使用 |
| JP2002504342A (ja) * | 1998-02-19 | 2002-02-12 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 一価ｍｈｃ結合ドメイン融合タンパク質および接合体、多価ｍｈｃ結合ドメイン融合タンパク質および接合体、ならびに多量体ｍｈｃ結合ドメイン融合タンパク質および接合体、そしてそれらのための使用 |
| EP1244708B8 (en) * | 1999-12-23 | 2007-03-07 | ZymoGenetics, Inc. | Method for treating inflammation |
| EP1777294A1 (en) | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
| CN101743249B (zh) * | 2007-05-11 | 2017-08-08 | 阿尔托生物科学有限公司 | 融合分子与il‑15变异体 |
| US8507222B2 (en) * | 2010-09-21 | 2013-08-13 | Altor Bioscience Corporation | Multimeric IL-15 soluble fusion molecules and methods of making and using same |
| EP2537933A1 (en) * | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | An IL-15 and IL-15Ralpha sushi domain based immunocytokines |
| WO2014177459A2 (en) * | 2013-04-29 | 2014-11-06 | F. Hoffmann-La Roche Ag | Fc-receptor binding modified asymmetric antibodies and methods of use |
| PT3444271T (pt) | 2013-08-08 | 2022-01-05 | Inst Nat Sante Rech Med | Modulocinas baseadas em il-15 e no domínio sushi de il-15ralfa |
| RU2689717C2 (ru) * | 2014-01-08 | 2019-05-28 | Шанхай Хэнжуй Фармасьютикал Ко., Лтд. | Гетеродимерный белок il-15 и его применения |
| KR102762243B1 (ko) * | 2014-06-30 | 2025-02-05 | 알토 바이오사이언스 엘엘씨 | Il-15-베이즈드 분자 및 이의 사용 방법 |
| PL3235830T3 (pl) | 2014-12-19 | 2020-12-14 | Jiangsu Hengrui Medicine Co., Ltd. | Kompleks białkowy interleukiny 15 i jego zastosowanie |
| RU2656181C1 (ru) | 2016-07-13 | 2018-05-31 | Закрытое Акционерное Общество "Биокад" | Анти-pd-1-антитела, способ их получения и способ применения |
| MY203000A (en) * | 2016-10-14 | 2024-06-01 | Xencor Inc | Il15/il15r� heterodimeric fc-fusion proteins |
| EP4613776A3 (en) * | 2016-10-21 | 2025-11-26 | Altor BioScience Corporation | Multimeric il-15-based molecules |
| KR102867975B1 (ko) * | 2017-03-06 | 2025-10-14 | 알토 바이오사이언스 엘엘씨 | Il-12 및 il-18로의 il-15-기반 융합 |
| RU2665790C1 (ru) | 2017-04-17 | 2018-09-04 | Закрытое Акционерное Общество "Биокад" | Моноклональное антитело к pd-l1 |
| WO2019006472A1 (en) * | 2017-06-30 | 2019-01-03 | Xencor, Inc. | TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS |
| JP2020530280A (ja) * | 2017-07-03 | 2020-10-22 | トルク セラピューティクス， インコーポレイテッド | 免疫刺激性融合分子およびその使用 |
-
2019
- 2019-09-19 RU RU2019129569A patent/RU2753282C2/ru active
-
2020
- 2020-09-18 AR ARP200102607A patent/AR120011A1/es unknown
- 2020-09-20 PH PH1/2022/550688A patent/PH12022550688A1/en unknown
- 2020-09-20 CA CA3151780A patent/CA3151780A1/en active Pending
- 2020-09-20 PE PE2022000447A patent/PE20220603A1/es unknown
- 2020-09-20 MA MA56286A patent/MA56286B1/fr unknown
- 2020-09-20 BR BR112022005173A patent/BR112022005173A2/pt unknown
- 2020-09-20 WO PCT/RU2020/050233 patent/WO2021054867A1/ru not_active Ceased
- 2020-09-20 KR KR1020227013100A patent/KR20220145323A/ko active Pending
- 2020-09-20 JP JP2022518285A patent/JP2022549276A/ja active Pending
- 2020-09-20 MX MX2022003306A patent/MX2022003306A/es unknown
- 2020-09-20 CN CN202080080165.8A patent/CN115297885A/zh active Pending
- 2020-09-20 EP EP20865705.6A patent/EP4032539A4/en active Pending
- 2020-09-20 AU AU2020351560A patent/AU2020351560A1/en active Pending
- 2020-09-20 US US17/761,838 patent/US20230011234A1/en active Pending
- 2020-09-21 TW TW109132634A patent/TWI891660B/zh active
- 2020-09-21 PY PY202002056649A patent/PY2056649A/es unknown
- 2020-09-22 UY UY0001038889A patent/UY38889A/es unknown
-
2022
- 2022-03-17 JO JOP/2022/0071A patent/JOP20220071A1/ar unknown
- 2022-03-18 ZA ZA2022/03254A patent/ZA202203254B/en unknown
- 2022-03-18 CO CONC2022/0003156A patent/CO2022003156A2/es unknown
-
2025
- 2025-07-14 JP JP2025118407A patent/JP2025182218A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022549276A5 (https=) | ||
| RU2019129569A (ru) | ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ | |
| JP7464764B2 (ja) | 抗ｒｏｒ１抗体とその作製及び使用方法 | |
| JP7685095B2 (ja) | 多重特異性抗体とその作製及び使用方法 | |
| JP7356970B2 (ja) | 多重特異性抗体とその作製及び使用方法 | |
| May et al. | Advances in bispecific biotherapeutics for the treatment of cancer | |
| JP2021525087A5 (https=) | ||
| JP2022521937A5 (https=) | ||
| US20250270338A1 (en) | Antibodies for t-cell activation | |
| CN116948035A (zh) | 多特异性抗体及其制备和使用方法 | |
| JP2023545099A5 (https=) | ||
| CN111094339B (zh) | 抗pd-1抗体和抗lag-3抗体联合在制备治疗肿瘤的药物中的用途 | |
| JP2024504372A5 (https=) | ||
| JP2022532991A5 (https=) | ||
| CN112969718A (zh) | Il-15蛋白复合物联合pd-l1抗体用于治疗肿瘤疾病的用途 | |
| CN117679505A (zh) | 药物组合及用途 | |
| JP2024527576A5 (https=) | ||
| US6007807A (en) | Induction of tumour immunity by injection of hybrid cells | |
| JPH05506037A (ja) | インターロイキン２レセプターに対するモノクローナル抗体 | |
| De Jonge et al. | Bispecific antibody treatment of murine B cell lymphoma | |
| RU2020140807A (ru) | Иммуноцитокин для активации IL-10Rα рецептора человека и его применение | |
| EP4696715A1 (en) | Medical use of anti-ctla4 and anti-pd-1 bispecific antibody | |
| Wang et al. | The development of a next generation NK cell engager platform by integrating a potency-reduced IL-15 variant to enhance antitumor activity | |
| NZ763865B2 (en) | Antibodies specific to cd47 and pd-l1 | |
| Huang | Engineered bispecific antibodies as cancer therapy |